Stay updated on Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    A site-wide NIH transition notice appears above the 403 error message, and the site revision changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T23:48:34.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-07T00:46:35.000Z thumbnail image
  4. Check
    33 days ago
    Change Detected
    Summary
    The page now renders a 403 Forbidden error page in place of the study details, signaling an access restriction or server issue preventing the study record from loading.
    Difference
    20%
    Check dated 2026-09-23T00:57:23.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.7.0, replacing the previous Revision: v3.6.6. This indicates a small editorial update to the page content and formatting.
    Difference
    0.1%
    Check dated 2026-09-16T00:14:05.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    A new revision tag, v3.6.6, was added and the previous tag, v3.6.5, was removed, indicating a minor version update on the page.
    Difference
    0.1%
    Check dated 2026-09-01T19:42:00.000Z thumbnail image
  7. Check
    76 days ago
    Change Detected
    Summary
    Revision updated from v3.6.4 to v3.6.5, representing a maintenance update to the page without altering study details or user-facing information.
    Difference
    0.0%
    Check dated 2026-08-11T12:54:09.000Z thumbnail image

Stay in the know with updates to Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page.